Vince Wacher, PhD

Theriva Biologics

Disclosure(s): Theriva Biologics: Contracted to Theriva Biologics and holds Theriva shares, Stocks/Bonds (Public Company)

Poster(s):

• (P-104) Safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET